RACHEL HIGH: Open Payments
NPI 1386162808 · OAKLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 25 payments from 17 companies in 2025. Trend: 2023 $34 · 2024 $614 · 2025 $766
Food & beverage: $467Education: $300
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 4 | $145 |
| SEAGEN INC. | 1 | $100 |
| Gilead Sciences, Inc. | 1 | $100 |
| Janssen Biotech, Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 1 | $58 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Tempus AI, Inc | 2 | $39 |
| Eisai Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $22 |
Products named: Trodelvy, GEMTESA, JAKAFI, PLUVICTO, XT CDX, Lenvima, TECVAYLI, KEYTRUDA.
Industry payments across MD — which companies pay providers there.
